Slide 1: Exchange filing cover letter: Presentation of Q2 FY24 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/SP/2023-24/115 November 11, 2023 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of
Slide 2: Q2 FY24 Earnings Call
Q2 FY24 Earnings Call November 10, 2023
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Chairperson Opening Remarks
Chairperson Opening Remarks
Slide 5: Group Financials Highlights: Q2 FY24
Group Financials Highlights : Q2 FY24 Consolidated (in ₹ Cr.) Q2 FY24 Q2 FY23 YoY % Total Revenue 3,620 2,384 52 Biosimilars 1,969 997 97 Research Service 910 768 18 Generics 676 652 4 Core EBITDA1 1,100 815 35 % Margin 32% 35%
Slide 6: Leadership Appointments
Leadership Appointments Kedar Upadhye Peter Bains Chief Financial Officer, Biocon Biologics Group CEO
Slide 7: Group CEO Opening Remarks
Group CEO Opening Remarks $ Biocon
Slide 8: Key Leadership Appointments
Key Leadership Appointments Dr. Arlene Wolny Dr. Uwe Gudat Global Head of Regulatory Affairs Chief Medical Officer Biocon Biologics Biocon Biologics Ramprasad Bhat Nitin Tiwari Head – Branded Formulations India Quality Head, Biocon Limited Biocon Biologics
Slide 9: Financial Highlights Q2 FY24
Financial Highlights Q2 FY24
Slide 10: Financial Highlights: Q2 FY24
Financial Highlights: Q2 FY24 Consolidated (in ₹ Cr.) Q2 FY24 Q2 FY23 YoY % Total Revenue 3,620 2,384 52 Biosimilars +97% | Research +18% | Generics +4% Core EBITDA1 1,100 815 35 Growth across Generics, Biosimilars & Research Services % Margin 32% 35% Net R&D spend at ₹264 Cr, up ₹22 Cr vs Q2 FY23,
Slide 11: Financial Highlights: Q2 FY24 Net Profit and Exceptional Items
Financial Highlights: Q2 FY24 Consolidated (in ₹ Cr.) Q2 FY24 Q2 FY23 YoY % Net Profit 142 168 (16) (before exceptional charge) Exceptional items: • Q2 FY24 • PLI accrual reversal for last year • Stelis acquisition related expenses Exceptional Items (net of tax and minority interest) (16) (122) • Q2
Slide 12: Generics Q2 FY24
Generics Q2 FY24
Slide 13: Biocon Generics: Q2 FY24 Highlights
Biocon Generics: Q2 FY24 Highlights Performance driven by continued traction in our US generic formulations business and expansion in MoW markets. API business performance muted. In INR Cr Q2 FY24 Q2 FY23 YoY % Announced a partnership agreement with Juno Pharmaceuticals for the commercialization of
Slide 14: Biosimilars Q2 FY24
Biosimilars Q2 FY24
Slide 15: Biocon Biologics: Biosimilars – Q2 FY24 Business Update
Biocon Biologics: Biosimilars – Q2 FY24 Business Update Key Products’ Market Share1 Integrated North America business – seamless commercial operations from 1st September; remain on track to transition Europe, JANZ and the United States remaining Emerging Markets later during the year Sep-23 Jun-23 S
Slide 16: Biocon Biologics: Biosimilars – Q2 FY24 Financial Update
Biocon Biologics: Biosimilars – Q2 FY24 Financial Update Revenues marginally down despite significantly lower licensing In INR Cr Q2 FY24 Q1 FY24 QoQ % revenues versus last quarter Revenue 1,969 2,015 (2) Core EBITDA1 660 513 29 Excluding licensing revenues, sequential growth at 6%, reflecting under
Slide 17: Biocon Biologics: Biosimilars – Q2 FY24 Other Business Updates
Biocon Biologics: Biosimilars – Q2 FY24 Other Business Updates European Commission granted MA for Yesafili (bAflibercept): EU brand sales of ~$1.8 billion annually US FDA has issued a CRL for the BLA of our Insulin Aspart Key Catalysts Activation of near-term catalysts: bAdalimumab, bAspart and bBev
Slide 18: Novels Q2 FY24
Novels Q2 FY24
Slide 19: Novel Molecules: Bicara Therapeutics
Novel Molecules: Bicara Therapeutics* BCA 101 Recently presented updated, positive interim data from its ongoing, open-label Phase 1/1b dose expansion study of BCA101 in European Society for Medical Oncology (ESMO) Congress. Strong investigator interest to enroll patients in future studies US$108 mi
Slide 20: Research Services Q2 FY24
Research Services Q2 FY24 Syngene
Slide 21: Syngene: Q2 FY24 Update
Syngene: Q2 FY24 Update In INR Cr Q2 FY24 Q2 FY23 YoY % Revenue 910 768 18 Strong performance led by Development and Manufacturing Services; supported by sustained momentum in Dedicated Centers EBITDA 276 232 19 % of Revenue 30 30 In Manufacturing Services, Syngene continued to make good progress on
Slide 22: Concluding Remarks
Concluding Remarks
Slide 23: Concluding Remarks: Q2 FY24
Concluding Remarks: Q2 FY24 Biocon Biologics on track with its accelerated transition program to create a fully integrated globally scaled leading biosimilar enterprise Sustained momentum and market share gains seen with commercialized products in the U.S. and Europe demonstrates the effectiveness o
Slide 24: Q&A
Q&A